Direxion Daily S&P Biotech Bear 3X Shares (LABD) stock forecast & analysis
8.96
NYSEArca · USD
Up: +0.91, +11.3%
8.95Down: -0.02, -0.2%
1 analysis
Latest analysis: · verdict locked
- Open
- 8.03
- Previous close
- 8.05
- Day range
- 8.03 – 9.03
- 52-week range
- 5.81 – 33.40
- Volume (shares)
- 30.23M
- Net assets
- 138.40M
- Expense ratio
- 1.07%
- Shares outstanding
- Not available
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- Not available
- Market cap
- Not available
Market Scanner’s AI analysis of Direxion Daily S&P Biotech Bear 3X Shares (LABD), updated October 2026: LABD's recent price action showed short-term strength above its 50-day SMA, but remained below its 200-day SMA.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Direxion Daily S&P Biotech Bear 3X Shares (LABD) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
LABD's recent price action showed short-term strength above its 50-day SMA, but remained below its 200-day SMA.
The analyses covered LABD's recent price movements, noting its position relative to key moving averages and momentum indicators. While short-term trends indicated upward momentum, the long-term trend remained below the 200-day SMA. Fundamental data was unavailable, and no recent news was reported.
LABD technical picture
LABD's price action showed short-term strength, trading above its 50-day SMA and with positive momentum readings. However, the price remained below its 200-day SMA, indicating a longer-term bearish trend.
Factors discussed — upside
- Price is above the 50-day SMA ($7.20)
- Positive 7-day change (+19.1%)
- Positive 30-day change (+16.2%)
- 10-day EMA ($8.17) is below the current price
- RSI (62.65) trending towards overbought
Factors discussed — risks
- Price is below the 200-day SMA ($12.92)
- Technical Analysis
- Moving Averages
- Momentum Indicators
Summary updated .
LABD technical indicators
Common technical indicators for LABD, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 7.20 | Price above |
| 10-day exponential moving average | 8.17 | Price above |
| Relative strength index (14-day) | 62.66 | Neutral |
| MACD line (12/26/9) | 0.3514 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 6.45 – 8.87 | Price above the upper band |
Analyses
Recent LABD.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-18 LABD.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Direxion Daily S&P Biotech Bear 3X Shares?
- The recent analyses indicated short-term strength, with the price closing above its 50-day Simple Moving Average and showing positive 7-day and 30-day percentage changes. Momentum indicators like the 10-day Exponential Moving Average, Relative Strength Index, and Money Flow Index also suggested positive buying pressure and a trend towards overbought territory.
- What are the risks for Direxion Daily S&P Biotech Bear 3X Shares?
- The long-term trend for LABD remained a point of consideration, as the current price was still considerably below its 200-day Simple Moving Average.
- Is Direxion Daily S&P Biotech Bear 3X Shares bullish or bearish?
- Recent AI analyses of Direxion Daily S&P Biotech Bear 3X Shares examined factors on both sides. Discussed upside: The recent analyses indicated short-term strength, with the price closing above its 50-day Simple Moving Average and showing positive 7-day and 30-day percentage changes. Momentum indicators like the 10-day Exponential Moving Average, Relative Strength Index, and Money Flow Index also suggested positive buying pressure and a trend towards overbought territory. Discussed risks: The long-term trend for LABD remained a point of consideration, as the current price was still considerably below its 200-day Simple Moving Average. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Direxion Daily S&P Biotech Bear 3X Shares?
- The analyses covered LABD's recent price movements, noting its position relative to key moving averages and momentum indicators. While short-term trends indicated upward momentum, the long-term trend remained below the 200-day SMA. Fundamental data was unavailable, and no recent news was reported.
- How does Market Scanner analyse Direxion Daily S&P Biotech Bear 3X Shares?
- Every analysis of Direxion Daily S&P Biotech Bear 3X Shares runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Direxion Daily S&P Biotech Bear 3X Shares?
The recent analyses indicated short-term strength, with the price closing above its 50-day Simple Moving Average and showing positive 7-day and 30-day percentage changes. Momentum indicators like the 10-day Exponential Moving Average, Relative Strength Index, and Money Flow Index also suggested positive buying pressure and a trend towards overbought territory.
What are the risks for Direxion Daily S&P Biotech Bear 3X Shares?
The long-term trend for LABD remained a point of consideration, as the current price was still considerably below its 200-day Simple Moving Average.
Is Direxion Daily S&P Biotech Bear 3X Shares bullish or bearish?
Recent AI analyses of Direxion Daily S&P Biotech Bear 3X Shares examined factors on both sides. Discussed upside: The recent analyses indicated short-term strength, with the price closing above its 50-day Simple Moving Average and showing positive 7-day and 30-day percentage changes. Momentum indicators like the 10-day Exponential Moving Average, Relative Strength Index, and Money Flow Index also suggested positive buying pressure and a trend towards overbought territory. Discussed risks: The long-term trend for LABD remained a point of consideration, as the current price was still considerably below its 200-day Simple Moving Average. These are descriptive observations, not a recommendation.
What is the latest sentiment on Direxion Daily S&P Biotech Bear 3X Shares?
The analyses covered LABD's recent price movements, noting its position relative to key moving averages and momentum indicators. While short-term trends indicated upward momentum, the long-term trend remained below the 200-day SMA. Fundamental data was unavailable, and no recent news was reported.
How does Market Scanner analyse Direxion Daily S&P Biotech Bear 3X Shares?
Every analysis of Direxion Daily S&P Biotech Bear 3X Shares runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh LABD.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.